SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artŪculo

VILA CORCOLES, A. ¬†y¬† GRUPO DE ESTUDIO EVAN-65 et al. Efectividad de la vacuna antineumoc√≥cica en pacientes mayores de 65 a√Īos. Medifam [online]. 2003, vol.13, n.4, pp.61-68. ISSN 1131-5768.


    1.††Subdirección General de Prestaciones y Evaluación de Tecnologías Sanitarias. Ministerio de Sanidad y Consumo. Informe sobre vacuna neumocóccica. Med Clin (Barc) 1994; 10: 383-6. [ Links ]

    2.††Gil de Gómez Barragán MJ, Acítores Augusto JM. Vacuna antineumocóccica: ¿a quién hay que vacunar? FMC 1996; 3: 185-90. † [ Links ]

    3.††Pahissa Berga A. Vacunación antineumocócica. Tema pendiente de nuestra sanidad. Med Clin (Barc) 1991; 13: 499-501. [ Links ]

    4.††Cruz D, Planes A. Vacuna antineumocóccica: ¿ a quién hay que vacunar? FMC 1996; 3: 181-5. [ Links ]

    5.††Departament de Sanitat i Seguretat Social. Bulletí Epidemiològic de Catalunya 1995; 16: 102-10. [ Links ]

    6.††Departament de Sanitat i Seguretat Social. Generalitat de Catalunya. Llibre Blanc: bases per a la integració de la prevenció a la pràctica assistencial. Barcelona: Doyma, 1993. † [ Links ]

    7.††European Study on Community-Acquired Pneumonia (ESOCAP) Committee. Guidlines for management of adult community-adquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-91. † [ Links ]

    8.††Dorca J, Bello S, Blanquer J, De Celis P, Molinos L, Torres, et al. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol 1997; 33: 240-6. † [ Links ]

    9.††Niederman MS, Mandell LA, Anzueto A, Bass JE, Broghton WA, Campbell GD, et al. Guidelines for the management of adults with community-adquired pneumonia. Diagnosis, assessment of severety, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54. [ Links ]

    10.††Álvarez MJ, Mayer MA. El dilema sobre el coste efectividad de la vacuna antineumocócica sigue abierto. Medifam 2001; 3: 115-21. [ Links ]

    11.††Salleras L. Vacunación antineumocócica en la tercera edad. Vacunas Invest Pract 2000; 1: 55-8. [ Links ]

    12.††Plans P, Garrido O, Salleras L. Coste-efectividad de la vacunación neumocócica en Cataluña. Rev Esp Salud Pública 1995; 69: 409-17. [ Links ]

    13.††Forrester HL, Jahnigen DW, Laforce FM. Inefficacy of pneumococcal vaccine in a high risk population. Am J Med 1987; 83: 425-30. [ Links ]

    14.††Butler JC, Breiman RF, Campell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysacharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-131. [ Links ]

    15.††Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysacharyde vaccine. N Eng J Med 1991; 325: 1453-160. [ Links ]

    16.††R Andreu Moore, Philip J Wiffen, Benjamin A Lipsky. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Family Practice 2000; 1: 1. [ Links ]

    17.††Puig Barberà J, Belenguer Barea A, Goterris Pinto M, Brines Benlliure MJ. Efectividad de la vacuna frente al neumococo en el anciano. Revisión sistemática y metaanálisis. Aten Primaria 2002; 30: 269-83. [ Links ]

    18.††Aller AI, Garjón FJ, Buisán MJ, Palacín JC. ¿Está justificada la vacunación contra el neumococo en mayores de 65 años? Aten Primaria 2002; 7: 433-7. [ Links ]

    19.††Center for Disease Control and Prevention: Recommendations of the Advisory Committee on Innunization Practices, the American Academy of Pediatrics, and the Americademy of Family Physicians: use of reminder an recall by vaccination providers to increase vaccinations rates. MMWR 1998; 47: 715-7. [ Links ]

    20.††Center for Disease Control and Prevention: Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation-a report of the National Vaccine Advisory Committee. MMWR 2000; 49 (No. RR-1): 1-14. [ Links ]

    21.††Briss PA, Rodewald LE, Hinman AR, Shefer AM, Strikas RA, Bernier RR, et al. Task Force on Community Preventive Services. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescent, and adults. Am J Prev Med 2000; 18 (1) (Supl. 1): 97-140. [ Links ]

    22.††Arjimón JM, Jiménez, J. Métodos de investigación clínica y epidemiológica. 2ª ed. Barcelona: Harcourt, 1999. p. 350-1. [ Links ]

    23.††Gudiol F. Infecciones neumocócicas. En: Farreras P, Rozman C. Medicina Interna. 13ª ed. Barcelona: Doyma, 1997. p. 2266-98. [ Links ]

    24.††Álvarez Gutierrez FJ, García Fernandez A, Elías Hernández T, Romero Contreras J, Romero Romero B, Castillo Gómez J. Neumonías en pacientes mayores de 60 años no hospitalizados. Incidencia de gérmenes atípicos y evolución clínicorradiológica. Med Clin (Barc) 2001; 117: 441-5. [ Links ]

    25.††Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE. A prediction rule to identify low-risk patients with community-adquired pneumonia. N Engl J Med 1997; 336: 243-50. [ Links ]

    26.††Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999; 15 (Supl. 1): 21-30. [ Links ]

    27.††Salleras Ll, Urbiztondo Ll, Fernández N, Comín E, Sánchez F, Batalla J, et al. Vacunación antineumocócica en las personas mayores. Med Clin (Barc) 2001; 116: 18-23. [ Links ]

    28.††American Medical Association. Prevention of pneumococcal disease: use of the pneumococcal polysaccharide vaccine. Quality Care Alert, 1999. [ Links ]